Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
23 studies found for:    neurology AND University AND San Francisco | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Brain Development Research Program
Conditions: Brain Disorders;   Aicardi Syndrome
Intervention:
2 Recruiting Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
Condition: Pediatric Multiple Sclerosis
Intervention:
3 Recruiting Efficacy of Isradipine in Early Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Isradipine;   Drug: Placebo (for Isradipine)
4 Recruiting The Human Epilepsy Project
Condition: Focal Epilepsy
Intervention:
5 Recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
6 Recruiting Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
Condition: Huntington Disease
Intervention:
7 Recruiting Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Condition: Huntington's Disease
Intervention:
8 Recruiting Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)
Conditions: Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
9 Recruiting Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: other disease-modifying therapy
10 Recruiting Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037 (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
11 Recruiting Pediatric Open-Label Extension Study
Conditions: Schizophrenia;   Autism;   Bipolar Depression
Intervention: Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed
12 Recruiting Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Condition: Stroke
Interventions: Drug: GM602;   Drug: Matching Placebo (Bacteriostatic Saline) for GM602
13 Recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
14 Recruiting Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects
Condition: Alzheimer's Disease
Interventions: Drug: florbetapir F 18;   Drug: 18F-AV-1451
15 Recruiting Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Condition: Cognition Disorders
Interventions: Drug: Solanezumab;   Drug: Placebo
16 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237;   Drug: Placebo
17 Recruiting Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Condition: HER2 Low to Intermediate Breast Cancer
Interventions: Biological: NeuVax™ vaccine;   Biological: Leukine® (sargramostim, GM-CSF) and water for injection
18 Not yet recruiting Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
Condition: Familial Frontotemporal Dementia
Intervention:
19 Recruiting Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)
Conditions: Amyotrophic Lateral Sclerosis;   Frontal Temporal Dementia
Interventions: Drug: Memantine;   Drug: Placebo (for Memantine)
20 Recruiting Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Condition: Refractory Generalized Myasthenia Gravis
Interventions: Biological: Eculizumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years